Optimizing Treatment Strategies for HR+/HER2- Breast Cancer: ESR1 Mutations and Emerging Therapies : Episode 4
Opinion
Video
Case Presentation 1: PIK3CA Mutation With ESR1 Mutations
Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, present a patient case involving a 54-year-old postmenopausal woman diagnosed with a 2.1cm estrogen receptor positive (ER+), HER2 negative breast cancer, and discuss the clinical implications and management strategies for this specific patient scenario.
EP: 1.Prevalence and Testing Strategies for ESR1
EP: 2.Evolution of Testing Strategies for ESR1
EP: 3.Dynamics of ESR1 Alterations and Serial Liquid Biopsies
Now Viewing
EP: 4.Case Presentation 1: PIK3CA Mutation With ESR1 Mutations
EP: 5.EMERALD Study Design and Results for Elacestrant
EP: 6.Evolving Best Practices for ESR1 Testing
EP: 7.Case Presentation 2: Co-mutations in ESR1 and PIK3CA
EP: 8.PIK3CA Mutations and Delivering PI3K Inhibitors
EP: 9.PostMONARCH: Dissecting Data on Sequential CDK 4/6 Inhibitors
EP: 10.Combinations and Treatment Sequence Strategies in Breast Cancer
EP: 11.Future Directions and Unmet Needs in HR+ Breast Cancer
EP: 12.Looking Ahead: Expert Future Perspectives in HR+ Breast Cancer
- How does this truncal vs acquired distinction impact treatment strategies for ESR1 mutation-positive disease?
- What criteria are used to classify ESR1 mutations as truncal vs acquired?
Related Videos
Related Content
